PMID- 28447770
OWN - NLM
STAT- MEDLINE
DCOM- 20170428
LR  - 20180326
IS  - 1533-4406 (Electronic)
IS  - 0028-4793 (Linking)
VI  - 376
IP  - 17
DP  - 2017 Apr 27
TI  - Ocrelizumab in Primary Progressive and Relapsing Multiple Sclerosis.
PG  - 1692-3
LID - 10.1056/NEJMc1702076 [doi]
FAU - Mildiner, Sorcha
AU  - Mildiner S
AD  - Kaplan Medical Center, Rehovot, Israel
FAU - Malnick, Stephen
AU  - Malnick S
AD  - Kaplan Medical Center, Rehovot, Israel
AD  - stephen@malnick.net
LA  - eng
PT  - Letter
PT  - Comment
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
SB  - AIM
SB  - IM
CON - N Engl J Med. 2017 Jan 19;376(3):209-220. PMID: 28002688
CIN - N Engl J Med. 2017 Apr 27;376(17 ):1692-1694. PMID: 28445661
MH  - Humans
MH  - *Multiple Sclerosis
MH  - *Multiple Sclerosis, Relapsing-Remitting
MH  - Recurrence
EDAT- 2017/04/28 06:00
MHDA- 2017/04/30 06:00
CRDT- 2017/04/28 06:00
PHST- 2017/04/28 06:00 [pubmed]
PHST- 2017/04/30 06:00 [medline]
PHST- 2017/04/28 06:00 [entrez]
AID - 10.1056/NEJMc1702076 [doi]
AID - 10.1056/NEJMc1702076#SA2 [pii]
PST - ppublish
SO  - N Engl J Med. 2017 Apr 27;376(17):1692-3. doi: 10.1056/NEJMc1702076.